论文部分内容阅读
目的:观察3’-大豆苷元磺酸钠对慢性心力衰竭大鼠心肌受磷蛋白(phospholamban,PLB)和Ca2+-ATP酶(Ca2+-ATPase,SERCA)mRNA表达的影响,探讨3’-大豆苷元磺酸钠抗心力衰竭的机制。方法:结扎大鼠冠状动脉前降支造成心肌梗死后慢性充血性心力衰竭(CHF)模型,采用实时荧光定量PCR技术观察。心肌PLB和SERCA mRNA表达以及3’-大豆苷元磺酸钠对其影响。结果:各给药组均可不同程度的下调PLB mRNA表达,上调降低SERCA mRNA表达,其中3’-大豆苷元磺酸钠0.4mg.kg-1剂量组、地高辛组与模型组比较有显著性差异(P<0.05);各给药组均能降低PLB/SERCA比值,地高辛组和3’-大豆苷元磺酸钠0.4mg.kg-1、0.2mg.kg-1剂量组与模型组比较差异具有显著性(P<0.05,P<0.01)。结论:3’-大豆苷元磺酸钠治疗能提高SERCA mRNA表达,降低PLBmRNA表达,改善PLB/SER-CA比值,这可能是3’-大豆苷元磺酸钠抗心力衰竭的机制之一。
OBJECTIVE: To observe the effect of 3’-daidzein sulfonate on myocardial expression of phospholamban (PLB) and Ca2+-ATPase (SERCA) mRNA in rats with chronic heart failure, and to investigate 3’-daidzein The mechanism of sodium metasulfonate against heart failure. METHODS: The chronic congestive heart failure (CHF) model of myocardial infarction was induced by ligation of anterior descending coronary artery in rats and observed by real-time fluorescence quantitative PCR. Myocardial PLB and SERCA mRNA expression and its effect on 3’-daidzein sulfonate sodium. RESULTS: All the treatment groups could down-regulate the expression of PLB mRNA and up-regulate the expression of SERCA mRNA. Among them, the 3’-daidzein sodium sulfonate 0.4 mg.kg-1 dose group, digoxin group and model group had more Significant difference (P<0.05); PLB/SERCA ratios were reduced in all groups, digoxin group and 3′-daidzein sodium sulfonate 0.4 mg.kg-1, 0.2 mg.kg-1 dose group Compared with the model group, the difference was significant (P<0.05, P<0.01). Conclusion: The treatment with 3′-daidzein sulfonate can increase the expression of SERCA mRNA, decrease the expression of PLB mRNA, and improve the ratio of PLB/SER-CA. This may be one of the mechanisms of 3′-daidzein sulfonates against heart failure.